Assessing Reliability of Aging Clocks
The article discusses whether epigenetic and other aging clocks can reliably measure anti-aging interventions. It notes that different clocks may disagree and that no clock is guaranteed to capture a novel therapy's effects. Proposed confidence criteria include agreement among reliable clocks, mortality-trained clocks, and multiple clocks responding in the same direction.
Aging clocks use machine learning on large biological datasets to combine age-related measurements that track chronological age, mortality, or remaining lifespan. Their promise is faster evaluation of potential anti-aging treatments, but a clock may miss, exaggerate, or misread effects from a new therapy; calibrating it against that therapy would require long studies.
Epigenetic clocks are tied to illness and death and are increasingly used as intervention outcomes, yet separate clocks can disagree. A study extending single-clock analyses found no additional clocks became statistically significant. It proposed confidence criteria: reliable principal-component clocks respond, mortality-trained or pace-of-aging clocks respond, and multiple clocks move in the same direction.
The proposed criteria could influence how researchers, biotechnology firms, and funders interpret early anti-aging studies, potentially curbing reliance on a single clock. Consumers of longevity products may benefit if biomarker-based claims are viewed more cautiously. Clinicians and regulators may use such frameworks to weigh evidence, though real-world impact depends on further validation and agreement across studies.